256 related articles for article (PubMed ID: 33017743)
1. Design and synthesis of 3-(4-pyridyl)-5-(4-sulfamido-phenyl)-1,2,4-oxadiazole derivatives as novel GSK-3β inhibitors and evaluation of their potential as multifunctional anti-Alzheimer agents.
Wang M; Liu T; Chen S; Wu M; Han J; Li Z
Eur J Med Chem; 2021 Jan; 209():112874. PubMed ID: 33017743
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.
Saitoh M; Kunitomo J; Kimura E; Hayase Y; Kobayashi H; Uchiyama N; Kawamoto T; Tanaka T; Mol CD; Dougan DR; Textor GS; Snell GP; Itoh F
Bioorg Med Chem; 2009 Mar; 17(5):2017-29. PubMed ID: 19200745
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of novel (4-(1,2,4-oxadiazol-5-yl)phenyl)-2-aminoacetamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Liu T; Chen S; Du J; Xing S; Li R; Li Z
Eur J Med Chem; 2022 Jan; 227():113973. PubMed ID: 34752955
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of novel GSK-3β inhibitors as multifunctional agents against Alzheimer's disease.
Shi XL; Wu JD; Liu P; Liu ZP
Eur J Med Chem; 2019 Apr; 167():211-225. PubMed ID: 30772605
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Biological Evaluation of Novel Tetrahydroacridin Hybrids with Sulfur-Inserted Linkers as Potential Multitarget Agents for Alzheimer's Disease.
Wu X; Ze X; Qin S; Zhang B; Li X; Gong Q; Zhang H; Zhu Z; Xu J
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675602
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel quinolin-2-one derivatives as potential GSK-3β inhibitors for treatment of Alzheimer's disease: Pharmacophore-based design, preliminary SAR, in vitro and in vivo biological evaluation.
Abdo Moustafa E; Abdelrasheed Allam H; Fouad MA; El Kerdawy AM; Nasser Eid El-Sayed N; Wagner C; Abdel-Aziz HA; Abdel Fattah Ezzat M
Bioorg Chem; 2024 May; 146():107324. PubMed ID: 38569322
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel β-carboline derivatives as selective AChE inhibitors with GSK-3β inhibitory property for the treatment of Alzheimer's disease.
Liu W; Liu X; Liu W; Gao Y; Wu L; Huang Y; Chen H; Li D; Zhou L; Wang N; Xu Z; Jiang X; Zhao Q
Eur J Med Chem; 2022 Feb; 229():114095. PubMed ID: 34995924
[TBL] [Abstract][Full Text] [Related]
9. Stereoisomers of Schisandrin B Are Potent ATP Competitive GSK-3β Inhibitors with Neuroprotective Effects against Alzheimer's Disease: Stereochemistry and Biological Activity.
Hu XL; Guo C; Hou JQ; Feng JH; Zhang XQ; Xiong F; Ye WC; Wang H
ACS Chem Neurosci; 2019 Feb; 10(2):996-1007. PubMed ID: 29944335
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of benzimidazole-linked-1,3,4-oxadiazole carboxamides as GSK-3β inhibitors with in vivo antidepressant activity.
Tantray MA; Khan I; Hamid H; Alam MS; Dhulap A; Kalam A
Bioorg Chem; 2018 Apr; 77():393-401. PubMed ID: 29421716
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel harmine derivatives as GSK-3β/DYRK1A dual inhibitors for Alzheimer's disease treatment.
Qiu J; Feng X; Chen H; Liu W; Liu W; Wu L; Gao X; Liu Y; Huang Y; Gong H; Qi Y; Xu Z; Zhao Q
Arch Pharm (Weinheim); 2024 Feb; 357(2):e2300404. PubMed ID: 38010470
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Novel Tacrine-Pyrimidone Hybrids as Potent Dual AChE/GSK-3 Inhibitors for the Treatment of Alzheimer's Disease.
Yao H; Uras G; Zhang P; Xu S; Yin Y; Liu J; Qin S; Li X; Allen S; Bai R; Gong Q; Zhang H; Zhu Z; Xu J
J Med Chem; 2021 Jun; 64(11):7483-7506. PubMed ID: 34024109
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of thieno[3,2-
Yan N; Shi XL; Tang LQ; Wang DF; Li X; Liu C; Liu ZP
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1724-1736. PubMed ID: 35698879
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and anti-AD effects of dual inhibitor targeting glutaminyl cyclase/GSK-3β.
Xie Y; Chen C; Lin S; Yu X; Ye S; Chen X; Ouyang N; Xiong W; Li C; Xu C; Song G; Wu H
Eur J Med Chem; 2023 Feb; 248():115089. PubMed ID: 36638710
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of thieno[3,2-c]pyrazol-3-amine derivatives as potent glycogen synthase kinase 3β inhibitors for Alzheimer's disease.
Yan N; Xie F; Tang LQ; Wang DF; Li X; Liu C; Liu ZP
Bioorg Chem; 2023 Sep; 138():106663. PubMed ID: 37329814
[TBL] [Abstract][Full Text] [Related]
16. 2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta with good brain permeability.
Saitoh M; Kunitomo J; Kimura E; Iwashita H; Uno Y; Onishi T; Uchiyama N; Kawamoto T; Tanaka T; Mol CD; Dougan DR; Textor GP; Snell GP; Takizawa M; Itoh F; Kori M
J Med Chem; 2009 Oct; 52(20):6270-86. PubMed ID: 19775160
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel β-carboline-1,2,3-triazole hybrids as AChE/GSK-3β dual inhibitors for Alzheimer's disease treatment.
Liu W; Tian L; Wu L; Chen H; Wang N; Liu X; Zhao C; Wu Z; Jiang X; Wu Q; Xu Z; Liu W; Zhao Q
Bioorg Chem; 2022 Dec; 129():106168. PubMed ID: 36191431
[TBL] [Abstract][Full Text] [Related]
18. Design, Bio-evaluation and Molecular Dynamics Simulation of Novel GSK-3β Inhibitors.
Lyu W; Li Q; Li Q; Chen Y; Wang Y; Tang T; Feng F; Chi H; Li Y; Liu W; Sun H
Mol Inform; 2021 Dec; 40(12):e2060031. PubMed ID: 34323388
[TBL] [Abstract][Full Text] [Related]
19. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
20. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
